Pharmaceutical

InterPharma was established in 2008 as a pharmaceutical company with a license from the Ministry of Industry and trade of the Russian Federation No. 12570-LS-P 12 August, 2013, with current factory in Kabardino-Balkaria Republic to implement the production of medicines, manufacture, storage and sale of sterile medicines, production and storage of non-sterile and sale of medicines.

CDIL Subsidiary Sino KBR Pharmaceutical Limited has initiated a large scale investment, re-structuring plan, reactivation and expansion of a Russian pharmaceutical Inter Pharma plant in Kabardino-Balkaria to provide low cost and urgently needed medicines to consumers who pay greatly for similar medicines imported from the European Union and elsewhere.

  • The plant was founded in 1998 year Modernization: year 2009 total area: 39,000 m ² total area: 8.4 hectare specializes in production of infusion solutions.

  • The Company was established in 2008 as a pharmaceutical company with a license from the Ministry of Industry and Trade of the Russian Federation No. 12570-LS-P of 12th August, 2013, with current factory in Kabardina-Balkaria Republic to implement the production, manufacture, storage and sale of sterile medicines, and non-sterile medicines.

  • The Company is a limited liability company validly existing under the laws of Russian Federation and has full power and authority to own its assets and to carry on its business and has a paid-up share capital of 216,018,071 Russian Ruble.

  • The Company has invested over $30M USD in new top of the line pharmaceutical machinery and GMP licenses.

  • Sino KBR Pharmaceutical Limited has initiated its activity in the Kabardino-Balkaria Republic and Russia alongside with major affiliated PRC SOE’s and top financial institution from HK cooperating as a consortium to initiate large scale projects investments in the pharmaceutical industry in Kabardino-Balkaria Republic and Russia.

  • The Consortium will explore and invest additional synergetic take-over opportunities alongside with the subsidiary via merger and acquisition of complementary Russian pharmaceutical plants, and long term joint venture with large scale PRC’s pharma companies.

Quality

  • The implemented system of quality assurance and quality control at all stages of production, testing and distribution of products

  • Certificates:

    • ISO 14001: Environmental management system

    • Environmental management system

      • ISO 9001-quality management system: 2011 with respect to manufacture, storage and realization of sterile and non-sterile drugs

      • OHSAS 18001: Occupational health and safety management system

Strategy

  • We expend production immediately in the existing plant

  • We will receive a building for a broad and common administration for everything that is being restored there

  • Establishment of a plant for nutritional supplements – the building exists

  • Construction of an existing cosmetics plant.

  • Allocation of space and approval to another plant adjacent to the pharmaceuticals (in cooperation with an international patent manufacturer)

  • Setting up a marketing system – branches – offices – wholesalers – in the big cities, Moscow, St. Petersburg, and Rostov

Contact Us

Send Us a Message

Suite 5207, 52/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong, China

info@cdil.com.cn

Tel: +852-3892-8600

Fax: +852-2827-7733

© 2019 by China Development Integration Limited.